Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Preference tests

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    35 result(s) found for: Preference tests. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2017-001606-14 Sponsor Protocol Number: 2017/2555 Start Date*: 2017-10-10
    Sponsor Name:Gustave Roussy
    Full Title: A study of patient preference between ODM-201 and Enzalutamide in men with metastatic castrate-resistant prostate cancer
    Medical condition: Metastatic Castration resistant prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10076506 Castration-resistant prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-004159-19 Sponsor Protocol Number: 2018-00938 Start Date*: Information not available in EudraCT
    Sponsor Name:University Hospital Basel
    Full Title: Use of Copeptin Measurement after Arginine Infusion for the Diagnosis of Diabetes Insipidus - the CARGOx Study
    Medical condition: Polyuria-polydipsia syndrome (PPS) is divided into the three main entities central (complete or partial) diabetes insipidus (DI), nephrogenic DI and primary polydipsia (PP).
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing) NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-000686-19 Sponsor Protocol Number: MO05/6844 Start Date*: 2005-04-28
    Sponsor Name:University of Leeds
    Full Title: PACT (Patient Preferences in Adjuvant Colorectal Cancer Therapy) - A randomised crossover clinical trial comparing Bolus Fluorouracil/Leucovorin to Capecitabine as treatment for moderate to high ri...
    Medical condition: Moderate to high risk resected colorectal cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-003456-70 Sponsor Protocol Number: CTH-302 Start Date*: 2017-03-22
    Sponsor Name:Sunovion Pharmaceuticals Inc.
    Full Title: An Open-Label, Randomized, Crossover Trial utilizing a Single-Blinded Rater to evaluate APL-130277 compared to s.c. Apomorphine in Levodopa Responsive Subjects with Parkinson's Disease Complicated ...
    Medical condition: Levodopa Responsive Patients with Parkinson’s Disease Complicated by Motor Fluctuations ("OFF episodes")
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004852 10034006 Parkinson's disease aggravated LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) AT (Completed) ES (Ongoing) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-004423-36 Sponsor Protocol Number: MK-8616-104 Start Date*: 2015-01-12
    Sponsor Name:MSD Italia s.r.l.
    Full Title: Randomized, parallel group, controlled trial to compare two different “NMB + reversal” strategies in adult obese patients underwent laparoscopic abdominal surgery (Phase 4; Protocol No. MK-8616-104...
    Medical condition: Obese adults to be subjected to abdominal laparoscopic surgery
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-002153-30 Sponsor Protocol Number: MO40628 Start Date*: 2018-10-24
    Sponsor Name:Roche Farma S.A.(Soc Uni) que realiza el ensayo en España y que actúa como representante de F. Hoffmann-La Roche Ltd.
    Full Title: A randomized, multicenter, open-label cross-over study to evaluate patient preference and satisfaction of subcutaneous administration of the fixed-dose combination of pertuzumab and trastuzumab in ...
    Medical condition: Human epidermal growth factor receptor 2 (HER2)-positive Early Breast Cancer.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER-2 positive breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) PT (Completed) SE (Completed) FI (Completed)
    Trial results: View results
    EudraCT Number: 2018-003557-21 Sponsor Protocol Number: LixiBrain01 Start Date*: 2019-02-06
    Sponsor Name:University Hospital Tuebingen
    Full Title: Effect of insulin glargine and lixisenatide versus insulin glargine on brain insulin sensitivity in patients with type 2 diabetes
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-000075-27 Sponsor Protocol Number: HPN-100-021 Start Date*: 2016-03-07
    Sponsor Name:Horizon Therapeutics, LLC
    Full Title: A Randomised, Controlled, Open-Label Parallel Arm Study of the Safety, Pharmacokinetics and Ammonia Control of RAVICTI® (Glycerol Phenylbutyrate [GPB]) Oral Liquid and Sodium Phenylbutyrate (NaPBA)...
    Medical condition: Urea Cycle Disorders (UCDs)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000161833 10013373 Disorders of urea cycle metabolism LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed) AT (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2013-003976-11 Sponsor Protocol Number: HSG-1-13 Start Date*: 2014-01-24
    Sponsor Name:Helsinki University Central Hospital
    Full Title: Effects of S-1 and capecitabine in combination with oxaliplatin on the coronary artery blood flow in patients metastatic gastrointestinal tract adenocarcinoma
    Medical condition: Metastatic gastrointestinal tract adenocarcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Prematurely Ended) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2022-002492-11 Sponsor Protocol Number: PRECESTO Start Date*: 2023-09-13
    Sponsor Name:NFL BIOSCIENCES SA
    Full Title: Phase II Study Assessing Efficacy and Safety of NFL-101 on Reduction of Reinforcing Properties of Cigarettes
    Medical condition: Tobacco addiction
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004869 10043905 Tobacco use HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-003586-41 Sponsor Protocol Number: A6281289 Start Date*: 2007-12-17
    Sponsor Name:Pfizer Ltd. Ramsgate Road, Sandwich, Kent, CT13 9NJ, UK
    Full Title: Placebo-controlled trial on the efficacy of growth hormone replacement therapy in patients with growth hormone deficiency after traumatic brain injury
    Medical condition: Growth hormone deficiency after traumatic brain injury
    Disease: Version SOC Term Classification Code Term Level
    9.1 10056438 Growth hormone deficiency LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed) SE (Prematurely Ended) GB (Prematurely Ended) FR (Prematurely Ended) ES (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-005571-89 Sponsor Protocol Number: FM53 Start Date*: 2015-06-22
    Sponsor Name:Futura Medical Developments Ltd.
    Full Title: A randomized, double-blind, placebo-controlled, home use, cross-over clinical trial of topically-applied glyceryl trinitrate (GTN) for the treatment of Erectile Dysfunction
    Medical condition: This study investigates a drug intended for the treatment of male patients self-diagnosed with Erectile Dysfunction
    Disease: Version SOC Term Classification Code Term Level
    18.0 10038604 - Reproductive system and breast disorders 10061461 Erectile dysfunction PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2019-004471-39 Sponsor Protocol Number: IMR-SCD-301 Start Date*: 2020-06-24
    Sponsor Name:IMARA, Inc.
    Full Title: A Phase 2b Study to Evaluate the Safety and Efficacy of IMR-687 in Subjects with Sickle Cell Disease
    Medical condition: Sickle Cell Disease
    Disease: Version SOC Term Classification Code Term Level
    21.0 10010331 - Congenital, familial and genetic disorders 10040644 Sickle cell disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) NL (Prematurely Ended) GR (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-001094-33 Sponsor Protocol Number: BO39182 Start Date*: 2016-08-08
    Sponsor Name:Roche Farma, S.A., que representa en España a F. Hoffmann-La Roche Ltd.
    Full Title: A MULTICENTER, OPEN-LABEL, PHASE III STUDY TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF EMICIZUMAB GIVEN EVERY 4 WEEKS (Q4W) IN PATIENTS WITH HEMOPHILIA A
    Medical condition: Hemophilia A
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004850 10018938 Haemophilia A (Factor VIII) LLT
    19.0 100000004850 10053751 Hemophilia A with anti factor VIII LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Temporarily Halted) PL (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2012-002237-11 Sponsor Protocol Number: ARC Start Date*: 2012-12-17
    Sponsor Name:King's College London [...]
    1. King's College London
    2. South London and Maudsley NHS Foundation Trust
    Full Title: Effectiveness of Adaptive Opioid Agonist Maintenance Pharmacotherapy and Behavioural Therapy for Opioid Use Disorder.
    Medical condition: Opiate dependency disorder
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-004366-25 Sponsor Protocol Number: MO39129 Start Date*: 2017-10-09
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A SINGLE-ARM, MULTICENTER PHASE IIIB CLINICAL TRIAL TO EVALUATE THE SAFETY AND TOLERABILITY OF PROPHYLACTIC EMICIZUMAB IN HEMOPHILIA A PATIENTS WITH INHIBITORS
    Medical condition: Hemophilia A
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10060612 Hemophilia A LLT
    20.0 100000004850 10053751 Hemophilia A with anti factor VIII LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed) GB (GB - no longer in EU/EEA) DE (Completed) DK (Prematurely Ended) HU (Completed) ES (Completed) PL (Completed) FI (Completed) BE (Completed) SE (Completed) NL (Completed) IT (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2004-001557-29 Sponsor Protocol Number: A2171035 Start Date*: 2006-11-24
    Sponsor Name:Pfizer Inc.
    Full Title: A 52-WEEK MULTICENTER, OPEN-LABEL, RANDOMIZED, PARALLEL, TWO - ARM STUDY COMPARING EXUBERA® (INHALED HUMAN INSULIN) VS. HUMALOG® (INSULIN LISPRO), BOTH IN COMBINATION WITH INSULIN GLARGINE IN SUBJE...
    Medical condition: Type 1 Diabetes
    Disease: Version SOC Term Classification Code Term Level
    8.1 10045228 Type I diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended) DE (Prematurely Ended) GB (Prematurely Ended) NL (Completed) IE (Prematurely Ended) AT (Prematurely Ended) FI (Prematurely Ended) FR (Completed) SE (Prematurely Ended) BE (Completed) PT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-003315-60 Sponsor Protocol Number: A201 Start Date*: 2020-11-10
    Sponsor Name:Criceto IKM B.V.
    Full Title: A phase 1/2 study investigating the pharmacokinetics, safety and efficacy of a highly concentrated buccal formulation of apomorphine (APORON®) in subjects with Parkinson's Disease
    Medical condition: Parkinson's Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-001355-23 Sponsor Protocol Number: 40960 Start Date*: 2014-08-29
    Sponsor Name:Leiden University Medical Center
    Full Title: Ephedrine as add-on therapy for patients with myasthenia gravis
    Medical condition: myasthenia gravis
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029205 - Nervous system disorders 10028417 Myasthenia gravis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-002313-22 Sponsor Protocol Number: ADV6770-A11CS Start Date*: Information not available in EudraCT
    Sponsor Name:ADVICENNE PHARMA SA
    Full Title: A randomised, active controlled, open-label, 2-way cross-over, multicentre study to investigate the palatability, acceptability, pharmacokinetics, safety and tolerability, and treatment compliance ...
    Medical condition: Children with chilhood absence epilepsy.
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029205 - Nervous system disorders 10000332 Absence seizures HLT
    19.0 10029205 - Nervous system disorders 10034759 Petit mal epilepsy PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 17 13:14:11 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA